AMLCTL

AMLCTL refers to ex-vivo expanded, autologous cytotoxic T lymphocytes (CTLs) specifically reactive against a patient's own acute myeloid leukemia (AML) cells. Developed by Thomas A. Lane, MD, at the University of California, San Diego, this cell therapy is intended to augment autologous hematopoietic stem cell transplantation (AHSCT). The process involves harvesting T cells from the patient, expanding them in the presence of inactivated AML cells to select for leukemia-reactive clones, and then re-infusing them into the patient post-transplant. The therapeutic goal is to eliminate residual disease and prevent relapse in patients who are in complete remission but remain at high risk for recurrence.

Other names

Autologous AML-reactive cytotoxic T cellsAML-reactive CTLsEx-vivo expanded cytotoxic autologous AML-reactive T cells